Pure Global
NCT05914831

Ultra-hypofractionated for Whole Breast Irradiation (WBI) Compared to Partial Breast Irradiation (PBI)

Ultra-hypofractionated for Whole Breast Irradiation (WBI) Compared to Partial Breast Irradiation (PBI): A Single-Institution Prospective Phase 2 Trial
Oncology Institute of Vojvodina·Phase 2·ClinicalTrials.gov·radiationRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Breast Cancer Female
Drug/Device/Intervention
Ultra-fractionated WBI
Study type
Interventional
Intervention type
radiation
Sponsor & location
Primary sponsor
Oncology Institute of Vojvodina
Location
Novi Sad, Serbia
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2023
End date
May 31, 2033
Enrollment
100 participants
Primary outcome

Acute toxicity,Late toxicity

Summary

Female patients undergoing surgical treatment for early breast cancer and meeting the
 inclusion criteria for adjuvant breast radiotherapy were randomized into two groups. One
 group will receive adjuvant whole-breast radiotherapy in ultra-hypofractionated regimen of 26
 Gy in 5 fractions. In contrast, the other group will receive partial breast irradiation with
 a dose of 26Gy in 5 fractions.
 
 The study's objective is to compare the effects of both breast radiotherapy protocols in
 terms of locoregional disease control and survival and to compare the adverse effects of
 radiotherapy between the two protocols. To determine if there is a correlation between
 different parameters and the efficacy and degree of toxicity for both protocols.

ICD-10 classifications
Malignant neoplasm: Breast, unspecifiedMalignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedPersonal history of malignant neoplasm of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05914831
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05914831 through Pure Global AI's free database. This Phase 2 trial is sponsored by Oncology Institute of Vojvodina and is currently Recruiting. The study focuses on Breast Cancer Female. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.